Press Releases from the ATS International Conference

HomeAboutNewsroomPress ReleasesPress Releases from the ATS International Conference ▶ In VOYAGE Phase 3 Clinical Trial, Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11
In VOYAGE Phase 3 Clinical Trial, Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11

FOR RELEASE: Embargoed Until 10 a.m. EDT, Wednesday, May 19, 2021

In VOYAGE Phase 3 Clinical Trial, Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11

Session: D7

Abstract Presentation Time: 10 a.m. EDT, Wednesday, May 19, 2021


ATS 2021, New York, NY – Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference.  VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

Dupilumab also rapidly improved lung function within two weeks, an improvement that was sustained for up to 52 weeks (the length of the trial), compared to placebo.

“We hope results from the VOYAGE trial will lay the groundwork for dupilumab as a potential new treatment option for patients aged 6 to 11 with moderate-to-severe asthma,” said study author/investigator Leonard B. Bacharier, MD, professor of pediatrics, allergy/immunology/pulmonary medicine, Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center.  “We also hope this study will lead to better characterization and understanding of the role of type 2 inflammation in asthma in pediatric patients.”

Type 2 inflammation underlies most cases of asthma in children.

Dupilumab has previously been shown to be effective and have a demonstrated safety profile in adolescents and adults with moderate-to-severe asthma, patients six years of age and older with moderate-to-severe atopic dermatitis, and adults with chronic rhinosinusitis with nasal polyposis. 

VOYAGE investigators enrolled 408 children ages 6-11 with uncontrolled moderate-to-severe asthma in the trial. The researchers performed pre-specified primary analyses in two populations in the study:  350 patients with markers of type 2 inflammation (baseline blood eosinophils ≥150 cells/μl or fractional exhaled nitric oxide (FeNO) ≥20 ppb) and 259 patients with baseline blood eosinophils ≥300 cells/µl. Eosinophils are a type of white blood cell that can cause lung inflammation in people with asthma.

Patients receiving high-dose inhaled corticosteroid alone or medium-to-high dose inhaled corticosteroid with a second asthma controller were randomized to either receive 100 mg or 200 mg subcutaneous (under the skin) dupilumab or a matched placebo for up to 52 weeks.  In VOYAGE, for each participant randomized to receive placebo, two participants were randomized to receive dupilumab.

Dupilumab reduced patients’ exacerbation rate by 59.3 percent, improved FEV1pp (the first second of forced exhalation) and reduced FeNO (a measure of airway inflammation) significantly at 12 weeks as compared to placebo.  At week 24, patients treated with dupilumab showed greater improvement scores as compared to placebo on the Asthma Control Questionnaire Interviewer Administered, in which interviewees answer questions on asthma control..  Safety results were generally consistent with the known safety profile of dupilumab in patients aged 12 years and older with moderate-to-severe asthma. Median blood eosinophil values decreased to below the baseline level by the 52nd week in the dupilumab group.

“The effect of dupilumab on improving lung function in these children was particularly impressive,” noted Dr. Bacharier.  “Decreased lung function is associated with an increased risk of future asthma exacerbations. In addition, impaired lung function can result in abnormal lung growth. In this trial, dupilumab demonstrated significant and rapid improvement in lung function within two weeks that was sustained for up to 52 weeks, compared to placebo.” 

The type 2 inflammatory asthma phenotype can be identified by elevated blood or sputum eosinophil levels, elevated IgE levels (a type of antibody), increased levels of exhaled nitric oxide, and/or the presence of allergic asthma. Other type 2 inflammatory conditions, such as atopic dermatitis, food allergy, and allergic rhinitis, commonly co-exist in children with type 2 asthma. 

Type 2 inflammation results from the increased release of chemical messengers (including interleukins [IL]-4, IL-5, and IL-13) by certain cells of the immune system. These type 2 interleukins drive abnormal changes in the airway leading to clinical features of asthma, such as wheezing, shortness of breath, and coughing. Dupilumab is a fully human monoclonal antibody that inhibits the signaling of IL-4 and IL-13.

This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc.